RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Fusion Pharm Stock

Fusion Pharm EBIT 2024

Fusion Pharm EBIT

298,440 USD

Ticker

FSPM

ISIN

US36113H1005

WKN

A1H9CD

In 2024, Fusion Pharm's EBIT was 298,440 USD, a -191.09% increase from the -327,640 USD EBIT recorded in the previous year.

The Fusion Pharm EBIT history

YEAREBIT (undefined USD)
2012298.44
2011-327.64
1997-304
1996-2,254
1995-2,522
1994-982

Fusion Pharm Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Fusion Pharm, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Fusion Pharm from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Fusion Pharm’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Fusion Pharm. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Fusion Pharm’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Fusion Pharm’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Fusion Pharm’s growth potential.

Fusion Pharm Revenue, EBIT and net profit per share

DateFusion Pharm RevenueFusion Pharm EBITFusion Pharm Net Income
2012808,400 undefined298,440 undefined265,210 undefined
2011227,440 undefined-327,640 undefined-402,380 undefined
199730,000 undefined-304,000 undefined-406,000 undefined
1996883,000 undefined-2.25 M undefined-883,000 undefined
19957.99 M undefined-2.52 M undefined-2.28 M undefined
19948.28 M undefined-982,000 undefined-1.16 M undefined

Fusion Pharm stock margins

The Fusion Pharm margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fusion Pharm. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fusion Pharm.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Fusion Pharm's sales revenue. A higher gross margin percentage indicates that the Fusion Pharm retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Fusion Pharm's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Fusion Pharm's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Fusion Pharm's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Fusion Pharm. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Fusion Pharm's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Fusion Pharm Margin History

Fusion Pharm Gross marginFusion Pharm Profit marginFusion Pharm EBIT marginFusion Pharm Profit margin
201283.67 %36.92 %32.81 %
201130.55 %-144.06 %-176.92 %
1997-680 %-1,013.33 %-1,353.33 %
1996-236.92 %-255.27 %-100 %
1995-13.73 %-31.56 %-28.5 %
1994-2.86 %-11.87 %-14.03 %

Fusion Pharm Aktienanalyse

What does Fusion Pharm do?

Fusion Pharm Inc is a well-known company in the agricultural industry that operates in various business sectors. It was founded in 2010 by Scott Dittman with the idea of improving agricultural efficiency through the use of innovative technologies. Fusion Pharm has gradually built different business areas focused on the development and marketing of products for optimizing agriculture. One of Fusion Pharm's core areas is the production of modular cultivation systems for plants that utilize cutting-edge technologies. These systems, called "PharmaCubes," are designed to provide optimal conditions for plants and achieve higher crop yields. They are particularly intended for use in urban spaces and other environments where traditional cultivation methods may not be feasible. The advantage of these systems lies in their scalability, and they are optimized for indoor use. Another important business area for Fusion Pharm is the production of fertilizers and other agricultural chemicals. These products are marketed under the brand name "Agritabs" and are aimed at promoting healthier plant growth and higher crop yields. The agricultural chemicals are made from natural raw materials, making them more environmentally friendly than many other products on the market. They are intended for use in various industries, including agriculture, gardening and landscaping, and the food industry. In addition to manufacturing and supplying cultivation systems, Fusion Pharm also operates in the production and distribution of natural fertilizers and other agricultural chemicals. The company has also undertaken a pilot project for closed-room fish farming and established itself in the aquaculture industry. In recent years, the company has pursued an aggressive acquisition strategy to expand into new business fields. One of these acquisitions was the takeover of the cloud-based software company "CannaCube," which has developed a management system for cannabis cultivation. Through the acquisition of CannaCube, Fusion Pharm has now positioned its portfolio for the growing cannabis industry. The company has made a name for itself in the agricultural industry by optimizing existing processes for sustainable and efficient plant development. With its innovative technology and products, the company contributes to greater efficiency and a more environmentally friendly agricultural industry. Fusion Pharm ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Fusion Pharm's EBIT

Fusion Pharm's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Fusion Pharm's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Fusion Pharm's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Fusion Pharm’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Fusion Pharm stock

How much did Fusion Pharm achieve in EBIT for the current year?

In the current year, Fusion Pharm has achieved an EBIT of 298,440 USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Fusion Pharm.

How has the EBIT of Fusion Pharm developed in recent years?

The EBIT of Fusion Pharm has increased by -191.088% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Fusion Pharm?

The EBIT of Fusion Pharm is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Fusion Pharm pay?

Over the past 12 months, Fusion Pharm paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fusion Pharm is expected to pay a dividend of 0 USD.

What is the dividend yield of Fusion Pharm?

The current dividend yield of Fusion Pharm is .

When does Fusion Pharm pay dividends?

Fusion Pharm pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fusion Pharm?

Fusion Pharm paid dividends every year for the past 0 years.

What is the dividend of Fusion Pharm?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fusion Pharm located?

Fusion Pharm is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von Fusion Pharm kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fusion Pharm from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Fusion Pharm pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Fusion Pharm in the year 2023?

In the year 2023, Fusion Pharm distributed 0 USD as dividends.

In which currency does Fusion Pharm pay out the dividend?

The dividends of Fusion Pharm are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Fusion Pharm

Our stock analysis for Fusion Pharm Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fusion Pharm Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.